AUTEK(SZ:300595)2022-03-28 16:00Financial Performance - The company's operating revenue for 2021 was approximately ¥1.295 billion, representing a 48.74% increase compared to ¥870.66 million in 2020[33]. - The net profit attributable to shareholders for 2021 was approximately ¥554.74 million, an increase of 28.02% from ¥433.32 million in 2020[33]. - The net cash flow from operating activities reached approximately ¥630.09 million, marking a 65.41% increase from ¥380.94 million in 2020[33]. - The basic earnings per share for 2021 was ¥0.6536, up 27.21% from ¥0.5138 in 2020[33]. - Total assets at the end of 2021 were approximately ¥2.972 billion, a 34.32% increase from ¥2.213 billion at the end of 2020[33]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥2.216 billion, reflecting a 26.48% increase from ¥1.752 billion at the end of 2020[33]. - The company reported a non-operating income of approximately ¥52.48 million from financial products in 2021, compared to ¥49.10 million in 2020[38]. - The total revenue for 2021 reached ¥1,295,045,844.66, representing a year-on-year increase of 48.74% compared to ¥870,663,602.06 in 2020[70]. - The revenue from the medical sector surged by 180.78% year-on-year, amounting to ¥176,997,439.56, with a gross margin increase of 19.29%[74]. - The sales of orthokeratology lenses increased by 28.45% year-on-year, generating ¥669,915,613.52, although the gross margin slightly decreased by 0.55%[74]. Business Strategy and Expansion - The company plans to distribute a cash dividend of 1.46 RMB per 10 shares, based on a total of 850,508,170.00 RMB[16]. - The company is expanding its business into optometry services and full optometry products to diversify its product structure[11]. - The company plans to continue expanding its market presence and invest in new product development to enhance user experience[28]. - The company is focusing on enhancing production efficiency and capacity to meet growing demand in the orthokeratology lens market[84]. - The company plans to expand its optical service market by establishing joint ventures and self-operated optical terminals in regions with resource advantages, such as Nanjing and Hefei[130]. - The company aims to enhance its brand system by improving product variety and quality management, focusing on both product and service brand development[137]. - The company is expected to continue its growth trajectory with a focus on expanding its service offerings and geographical reach[87]. - The company has established a stable supply relationship with Bausch & Lomb for raw materials and is expanding partnerships with other suppliers to mitigate supply risks[141]. Research and Development - The company has a strong R&D team with over 20 years of experience in the hard contact lens field, holding complete independent intellectual property rights for various related technologies[52]. - The company is developing new products, including high-oxygen-permeable orthokeratology lenses and smart eye care devices, aimed at enhancing product lines and sales revenue[92][93]. - The company has invested in several new product development and medical technology companies, enhancing its position in the eye care industry and laying a solid foundation for high-quality investments[60]. - The company plans to increase investment in research and development, production capacity, quality improvement, and market expansion for rigid contact lenses[128]. - The company's R&D investment in 2021 amounted to ¥27,341,027.67, representing 2.11% of operating revenue, a slight decrease from 2.19% in 2020[95]. Market Risks and Challenges - The company faces risks related to the concentration of sales in the East China region, which still accounts for a significant portion of overall performance[12]. - The company acknowledges potential impacts from national healthcare reforms, particularly if its main products are included in insurance coverage and subject to bulk purchasing[8]. - The company is exposed to risks from fluctuations in gross profit margins due to increasing competition in the orthokeratology lens market[14]. - The company is currently not included in the medical insurance scope, which may affect future sales if policies change[8]. - The sales of orthokeratology lenses fluctuated due to the COVID-19 pandemic, with some regions experiencing temporary declines in business volume due to restrictions on non-emergency medical services[52]. Corporate Governance and Management - The company has established a robust internal control system, ensuring compliance with financial regulations and improving governance standards[153]. - The company has maintained a strong performance in corporate governance, with no unresolved issues reported in compliance with regulatory standards[155]. - The company has a diverse board of directors with backgrounds in engineering, finance, and law, contributing to its strategic decision-making[161]. - The company has a comprehensive compensation system based on performance evaluation, aiming to be competitive within the industry[182]. - The company has established a strong governance framework with independent directors contributing to its strategic oversight[166]. Financial Position and Investments - The company reported a significant increase in financing cash outflow, totaling ¥232,226,152.10, a rise of 339.47% compared to ¥52,842,517.85 in 2020[102]. - The net increase in cash and cash equivalents for 2021 was ¥328,981,203.55, a substantial increase of 204.30% from ¥108,109,892.19 in the previous year[103]. - The company has a total of 12 registration certificates for orthokeratology lenses, with increasing competition from new brands entering the market[43]. - The company has established multiple subsidiaries in 2021, including 12 new investments and 15 mergers under non-same control[87]. - The company has undergone several equity disposals, which may affect its operational structure and financial performance in the upcoming periods[88].